Biomerica’s Fast 15-Minute Easy to Use COVID-19 Antigen Test Now Available With Simple Nasal Swab
May 11 2021 - 7:19AM
Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced
medical products, announced that its new COVID-19 Antigen Rapid
Test can now be performed with a simple less invasive nasal swab.
This simple nasal swab, which takes the sample from the front
opening of the nose, is less invasive and more comfortable for
patients than the deep anterior nasal swab which is typically used.
The test is highly portable, cost effective and provides visual
results negating the need for any equipment to perform or read the
test. The test also provides results in 15 minutes versus lab-run
PCR tests which can take up to three days for results, thereby
potentially expediting the process of identifying infectious people
and preventing further spread of the virus.
Zack Irani, CEO at Biomerica, commented,
“COVID-19 testing will be with us well past the pandemic, and
ensuring that health care professionals have a simple, reliable
testing solution is imperative. Our nasal swab test is simple to
use, accurate and portable.”
Mr. Irani continued, “It is important to note
that while we continue to utilize and apply our diagnostic know-how
to COVID-19 tests, our primary focus remains the validation and
commercialization of our InFoods® diagnostic platform. We believe
that InFoods® is a revolutionary approach to the diagnosis and
treatment of Irritable Bowel Syndrome and other gastrointestinal
diseases and we continue to work tirelessly to bring these products
to market.”
About the Biomerica COVID-19 Rapid
Antigen Test: The Biomerica COVID-19 Rapid Antigen Test is
intended to identify people who are currently infected and who
should quarantine to help prevent the spread of the disease. No lab
equipment is necessary to process the test or read the tests
results. This test uses lateral flow technology, making it a
reliable and familiar format for mass testing by healthcare
providers. In independent testing at clinics in three different
countries outside of the U.S., the Biomerica COVID-19 Rapid Antigen
Test demonstrated an overall performance of 92.5% positive
agreement (sensitivity) and 100.0% negative agreement (specificity)
as compared to lab-based molecular PCR tests. The Biomerica
COVID-19 Rapid Antigen Test was engineered for near-patient,
point-of-care settings. A simple nasal swab is used to collect
specimens from people suspected of having an active infection.
Patient samples should be tested immediately and should not be
diluted or used with viral transport media or frozen specimens. The
test Is CE marked and targeted for use outside the United
States.
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical
technology company that develops, patents, manufactures and markets
advanced diagnostic and therapeutic products used at the point of
care (in home and in physicians' offices) and in hospital/clinical
laboratories for detection and/or treatment of medical conditions
and diseases. The Company's products are designed to enhance the
health and well-being of people, while reducing total healthcare
costs. Biomerica’s primarily focus is on gastrointestinal and
inflammatory diseases where the Company has multiple diagnostic and
therapeutic products in development.
About InFoods® The Biomerica
InFoods® IBS product is designed to allow physicians to identify
patient-specific foods (e.g., eggs, broccoli, wheat, potatoes,
pork, etc.), that when removed from the diet, may alleviate or
improve an individual's IBS symptoms including, but not limited to,
constipation, diarrhea, bloating, pain and indigestion. This
patented, diagnostic-guided therapy is designed to allow for a
patient-specific, guided dietary regimen to improve IBS outcomes. A
point-of-care version of the product is being developed to allow
physicians to perform the test in-office using a finger stick blood
sample, while a clinical lab version of the product is expected to
be the first for which the company will seek regulatory approval. A
billable CPT code that can be used by both clinical labs and
physicians' offices is already available for InFoods® products.
Since the InFoods® product is a diagnostic-guided therapy, and not
a drug, it has no drug type side effects. An estimated 45 million
people in America currently suffer from IBS making it a leading
cause for patient doctor visits.
The Private Securities Litigation Reform Act of
1995 provides a "safe harbor" for forward-looking statements.
Certain information included in this press release (as well as
information included in oral statements or other written statements
made or to be made by Biomerica) contains statements that are
forward-looking, such as statements relating to the efficacy of the
Company’s COVID-19 tests, FDA clearance of the Company’s products,
EUA clearance, the rapidity of testing results, uniqueness of the
Company’s products, test result accuracy of products, pricing of
the Company’s test kits, demand for domestic or international
orders, potential revenues from the sale of current or future
products, availability of the Company’s COVID-19 test kits, and
patent protection on any of the Company’s products or technologies.
Such forward-looking information involves important risks and
uncertainties that could significantly affect anticipated results
in the future, including, without limitation: results of studies
testing the efficacy of the Company’s COVID-19 tests, InFoods tests
and other products; regulatory approvals necessary prior to
commercialization of the Company’s products; availability of the
Company’s COVID-19 test kits and other products; capacity, resource
and other constraints on our suppliers; dependence on our third
party manufacturers; dependence on international shipping carriers;
governmental import/export regulations; demand for our various
COVID-19 tests and other products; competition from other similar
products and from competitors that have significantly more
financial and other resources available to them; governmental virus
control regulations that make it difficult or impossible for the
company to maintain current operations; regulations and the
Company’s ability to obtain patent protection on any aspects of its
rapid test technologies. Accordingly, such results may differ
materially from those expressed in any forward-looking statements
made by or on behalf of Biomerica. Additionally, potential risks
and uncertainties include, among others, fluctuations in the
Company's operating results due to its business model and expansion
plans, downturns in international and or national economies, the
Company's ability to raise additional capital, the competitive
environment in which the Company will be competing, and the
Company's dependence on strategic relationships. The Company is
under no obligation to update any forward-looking statements after
the date of this release.
Corporate Contact:
John Nesbett /Jennifer Belodeau IMS Investor
Relations 203.972.9200 jnesbett@institutionalms.com
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From Apr 2024 to May 2024
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From May 2023 to May 2024